| 000 | 01347 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250514031601.0 | ||
| 264 | 0 | _c20050628 | |
| 008 | 200506s 0 0 eng d | ||
| 022 | _a1526-8209 | ||
| 024 | 7 |
_a10.3816/cbc.2000.s.010 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPerez, E A | |
| 245 | 0 | 0 |
_aRationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer. _h[electronic resource] |
| 260 |
_bClinical breast cancer _cSep 2000 |
||
| 300 |
_aS52-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aEpirubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aResearch Design |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTaxoids _xadministration & dosage |
| 773 | 0 |
_tClinical breast cancer _gvol. 1 Suppl 1 _gp. S52-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3816/cbc.2000.s.010 _zAvailable from publisher's website |
| 999 |
_c11872311 _d11872311 |
||